Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, announced today the results of voting at its annual and special meeting of shareholders held earlier today (the “Meeting”). Each of the matters voted upon at the Meeting as set out below is …
Innovative Health, the leading single-use cardiology medical device reprocessing company, today announced it has received FDA clearance for reprocessing the market-leading PENTARAY® Nav eco High-Density mapping catheter (hereinafter PentaRay), a development that represents both a technological and healthcare cost reduction milestone. The PentaRay is a key medical device in Atrial Fibrillation (AF) procedures, one of …
MedTech Innovator, the premier nonprofit accelerator in the medical technology industry, today announced the 50 companies selected to participate in the organization’s flagship four-month program, featuring leading-edge device, diagnostic, and digital health technologies from around the world. These best-in-class startups will receive unparalleled visibility and access to leading manufacturers, providers, investors, and other industry stakeholders.
Colorescience®, leading dermatologist-recommended skincare and cosmetics company, is proud to announce that the United States Patent and Trademark Office has issued a patent covering formulations for treating, protecting and repairing skin around the eye area. These patents support Colorescience’s multifaceted formulation and product delivery method of Total Eye® Concentrate and Total Eye® 3-in-1 Renewal Therapy …
Colorescience® announces the published results of their study “Beyond sun protection factor: An approach to environmental protection with novel mineral coatings in a vehicle containing a blend of skincare ingredients” in The Journal of Cosmetic Dermatology, that assessed the efficacy of their proprietary EnviroScreen™ technology – a novel, patented formulation that fights against both sun …
Kelly Williams, Founding Chair and co-CEO of PEWIN said of the awards, “PEWIN is so pleased to recognize Luminate Capital, 1315 Capital, the Teacher Retirement System of Texas and The Riverside Company, each of whom are leading by example in their support, promotion and amplification of the outstanding women investors who exist in the private …
Greenbrook TMS Inc. (TSX:GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, announced today that it has completed its previously announced bought deal public offering and concurrent private placement (the “Offerings”) for total gross proceeds of C$30,579,250. The Offerings were both completed on a bought deal …
Misonix, Inc. (Nasdaq: MSON) (“Misonix”) a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, announced today that it has entered into a definitive agreement with Solsys Medical, LLC (“Solsys”), a privately held regenerative medical company, to acquire Solsys in an all-stock transaction valued at approximately $97 million. Under the terms of …
On the heels of National Rosacea Awareness Month, Colorescience® announces the published results in The Journal of Cosmetic Dermatology of an 18-week study that assessed the efficacy and tolerability of a daily use, multifunctional topical skin care regimen (All Calm® Clinical Redness Corrector SPF 50 and Sunforgettable® Brush-On Shield SPF 50) alone and in combination …
Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and cleantech industries, announced today it has provided a $20 million venture loan facility to Encore Dermatology, Inc. (“Encore”), of …
Encore Dermatology Inc. announced today that it has acquired rights for SERNIVO® (betamethasone dipropionate) Spray, 0.05%, as well as rights to market and distribute TRIANEX® 0.05% (Triamcinolone Acetonide Ointment, USP) and PROMISEB® Topical Cream in the United States from Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), through its wholly owned subsidiary Promius …
Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), through its wholly owned subsidiary Promius Pharma, LLC, announces the sale of its rights for SERNIVO® (betamethasone dipropionate) Spray, 0.05% and assignment of its rights to market and distribute, PROMISEB® Topical Cream and TRIANEX® 0.05% …